SecBot SecBot
8-K ·Filed Nov 5, 2026

INM

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 21h ago SEC0001193125-26-448367
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for the closing of the merger with Mentari Therapeutics, which remains subject to conditions. The creation of Series A Preferred Shares with conversion rights and board representation rights introduces potential future dilution and governance changes. The CVR issuance adds a contingent value component for existing shareholders.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$13.21
T+0 close · Nov 5, 2026 · via day close
Latest settled
+17.79%
T+1 · $15.56 · next T+5 due 5d ago
Vs SPY
+17.48%
α at T+1
Latest observation
+47.04%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $13.21entry
  2. T+1 · 11d ago +17.79%α +17.48% · $15.56
  3. T+5 · due 5d ago Pending
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals Inc. held its annual general and special meeting on November 4, 2026, where shareholders approved all proposals related to the pending merger with Mentari Therapeutics, including the Nasdaq share issuance, redomestication to Nevada, and the new stock incentive plan. The company also completed a 1-for-10 reverse stock split, changed its name to Mentari Therapeutics, Inc., and created a new series of non-voting convertible preferred shares (Series A Preferred) as part of the merger process.

Key Facts

  • Shareholders approved the Nasdaq share issuance proposal with 97.295% of votes for, authorizing the issuance of common shares representing more than 20% of outstanding shares to Mentari stockholders.
  • Shareholders approved the redomestication from British Columbia to Nevada with 88.825% of votes for.
  • Shareholders approved the Mentari Therapeutics 2026 Stock Incentive Plan with 88.615% of votes for.
  • The company completed a 1-for-10 reverse stock split, reducing outstanding common shares from 5,493,735 to approximately 549,374.
  • The company changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc., effective November 4, 2026.
  • The company created 4,013 Series A Non-Voting Preferred Shares, each convertible into 1,000 common shares, subject to a 19.99% beneficial ownership limitation.
  • All five director nominees were elected with over 89% of votes for each.
  • Shareholders approved the re-appointment of CBIZ CPAs P.C. as auditor with 95.943% of votes for.
  • The company expects to issue one contingent value right (CVR) per post-consolidation common share to holders of record as of November 5, 2026, contingent on future events.
  • The merger closing remains subject to satisfaction or waiver of remaining conditions.

Financial Impact

No financial figures disclosed in the filing. The reverse stock split reduced share count from 5,493,735 to approximately 549,374, with no change in proportionate equity.

share countdilution

Risk Factors

  • The merger may not close on the anticipated timeline or at all if conditions are not satisfied or waived.
  • The Series A Preferred Shares, if converted, could result in significant dilution to common shareholders (up to 4,013,000 common shares).
  • The beneficial ownership limitation on conversion of Series A Preferred Shares may be waived or changed by holders with 61 days notice, potentially increasing dilution risk.
  • The CVR payments are contingent on future events and may never materialize.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-448367
Document: d173223d8k.htm0001193125-26-448367
Document: d173223dex991.htm0001193125-26-448367
Document: d173223dex31.htm0001193125-26-448367
Document: 0001193125-26-448367-index-headers.html0001193125-26-448367
Document: 0001193125-26-448367-index.html0001193125-26-448367
Document: 0001193125-26-448367.txt0001193125-26-448367

Track record

22 reports on INM

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $13.21 Now $19.87 +50.42% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
  5. Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
  6. Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
  7. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
  8. Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
  9. Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
  10. Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026